Skip to content
10-Q

Quarterly Report

Amgen Inc. AMGN

0000318154-25-000020

← back to feed
Filed
May 2, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 28, 2025 537.71M sh
Long Term Debt Q1 2025 · Mar 31, 2025 $54.01B
Long Term Debt Q1 2025 · Dec 31, 2024 $56.55B
Cash And Equivalents Q1 2025 · Mar 31, 2025 $8.81B
Cash And Equivalents Q1 2025 · Dec 31, 2024 $11.97B
Current Liabilities Q1 2025 · Mar 31, 2025 $23.01B
Current Liabilities Q1 2025 · Dec 31, 2024 $23.1B
Current Assets Q1 2025 · Mar 31, 2025 $26.93B
Current Assets Q1 2025 · Dec 31, 2024 $29.03B
Total Assets Q1 2025 · Mar 31, 2025 $89.37B
Total Assets Q1 2025 · Dec 31, 2024 $91.84B
Shares Diluted Q1 2025 · Mar 31, 2024 536M sh
Dividends Paid Q1 2025 · Mar 31, 2024 $1.21B
Capex Q1 2025 · Mar 31, 2024 $230M
Operating Cash Flow Q1 2025 · Mar 31, 2024 $689M
Stockholders Equity Q1 2025 · Mar 31, 2024 $5.02B
Stockholders Equity Q1 2025 · Dec 31, 2023 $6.23B
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.21
Eps Basic Q1 2025 · Mar 31, 2024 −$0.21
Sga Expense Q1 2025 · Mar 31, 2024 $1.81B
Net Income Q1 2025 · Mar 31, 2024 −$113M
Operating Income Q1 2025 · Mar 31, 2024 $991M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $3.2B
Revenue Q1 2025 · Mar 31, 2024 $7.45B